Breaking News Instant updates and real-time market news.

XENT

Intersect ENT

$28.78

0.04 (0.14%)

, AET

Acquired by CVS

$203.76

0.22 (0.11%)

10:15
10/02/18
10/02
10:15
10/02/18
10:15

Intersect ENT's Sinuva reimbursement policies 'steps in right direction,' says Leerink

Leerink analyst Richard Newitter reiterates an Outperform rating on Intersect ENT following some positive progress on the reimbursement front for Sinuva in the last several weeks, namely Aetna (AET) covering Sinuva and Anthem (ATNM) adding it to its formulary this past week. The analyst believes these positive coverage policies represent steps in the right direction to a potentially quicker and more consistent reimbursement process using the specialty pharmacy channel, an area where the company has faced some challenges.

XENT

Intersect ENT

$28.78

0.04 (0.14%)

AET

Acquired by CVS

$203.76

0.22 (0.11%)

ANTM

Anthem

$276.46

0.27 (0.10%)

  • 27

    Nov

XENT Intersect ENT
$28.78

0.04 (0.14%)

05/07/18
PIPR
05/07/18
NO CHANGE
Target $45
PIPR
Overweight
Piper says CMS made error, buy shares of Intersect ENT
This morning on the Centers for Medicare & Medicaid Services website, the agency, in a preliminary assessment, assigned Intersect ENT's Sinuva a J-Code that is based on a CPT code for its Propel technology, which will be deleted at the beginning of next year, Piper Jaffray analyst Matt O'Brien tells investors in a research note. This appears to be an error on the part of CMS, the analyst adds. He fully anticipates it will be corrected in the final rule, which is expected to come out in November. O'Brien recommends investors take advantage of this morning's pullback to start or build positions in Intersect ENT. He doubts any clinicians would become concerned about the incorrect regulatory coding and does not anticipate any type of impact to the launch of Sinuva as a result. The analyst has an Overweight rating on Intersect ENT with a $45 price target. The stock in morning trading is down 6% to $39.15.
05/11/18
PIPR
05/11/18
NO CHANGE
Target $45
PIPR
Overweight
Intersect ENT selloff this week a buying opportunity, says Piper Jaffray
After hosting investor meetings with Intersect ENT management, Piper Jaffray analyst Matt O'Brien says J-code risk is overstated. Management spent a considerable amount of time discussing the preliminary J-Code ruling for Sinuva that came out earlier this week and noted that this was a clear clerical error, O'Brien tells investors in a research note. The analyst thinks the Sinuva launch is progressing well and that Intersect ENT's base business also has "significant room for growth." He believes investors should take advantage of the pullback earlier this week to start positions in the shares. O'Brien has an Overweight rating on Intersect ENT with a $45 price target.
08/01/18
PIPR
08/01/18
NO CHANGE
Target $40
PIPR
Overweight
Intersect ENT price target lowered to $40 from $45 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien lowered his price target for Intersect ENT to $40 from $45 after the company missed Q2 revenues and reduced full year 2018 guidance. Essentially, the disappointment in the quarter and for the outlook this year is the company's key new SINUVA product, which is ramping slower than expected due to reimbursement processing issues, he notes. Although this is disappointing and there is no guarantee that more road bumps in the launch will not pop up, the analyst still believes utilization will be quite strong and growth in 2019 and beyond will be among the best in small cap med tech. O'Brien reiterates an Overweight rating on the shares.
09/18/18
PIPR
09/18/18
NO CHANGE
Target $40
PIPR
Overweight
Intersect risk/reward favorable into reimbursement decision, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien see as favorable risk/reward for Intersect ENT shares ahead of the late November reimbursement decision for Sinuva. It is likely that Sinuva will get the J-code code either this year or next year, which can provide upside to 2018 and 2019 estimates, O'Brien tells investors in a research note. Further, not getting the code will merely represent a timing issue as clinicians will just need to get comfortable with reimbursement, the analyst adds. He believes that Sinuva's value is currently being mispriced regardless of the outcome and recommends shares of Intersect ENT with an Overweight rating and $40 price target.
AET Acquired by CVS
$203.76

0.22 (0.11%)

09/10/18
SDLR
09/10/18
INITIATION
Target $60
SDLR
Buy
Hartford Financial initiated with a Buy at Sandler ONeill
Sandler ONeill analyst Paul Newsome initiated Hartford Financial (HIG) with a Buy rating and $60 price target, citing his view that its valuation is "relatively attractive" and that the biggest near-term risk for investors has been resolved by the purchase of The Navigators Group (NAVG), which he sees having several benefits. Newsome also believes the recent acquisition of Aetna's (AET) benefits business will be a relatively strong earnings growth opportunity, he tells investors.
09/17/18
RBCM
09/17/18
NO CHANGE
Target $101
RBCM
Outperform
CVS Health price target raised to $101 from $90 at RBC Capital
RBC Capital analyst George Hill raised his price target on CVS Health (CVS) to $101 and kept his Outperform rating, citing the increased visibility of the company's merger with Aetna (AET) after its recent comments that it expects the deal to close in early Q4. The analyst also points to "de-risked" CVS investment thesis as it pertains to pharmacy benefit managers rebates and the much higher relative multiples for managed care companies, even though he warns that investors may still be spooked by any potential steps that the White House takes to drive prescription drug prices lower. Hill notes however that the latest government funding bill pulled the text that required drug companies to disclose prices in their ads, implying that the political will to change status quo may be limited.
08/27/18
RBCM
08/27/18
NO CHANGE
Target $94
RBCM
Outperform
Express Scripts price target raised to $94 from $90 at RBC Capital
RBC Capital analyst George Hills raised his price target on Express Scripts (ESRX) to $94 and kept his Outperform rating, citing the shareholders' "blessing" of the merger with Cigna (CI). The analyst notes that even though the regulators are yet to rule on the deal, he expects the merger to close by the end of the year and has a positive view of the "vertical consolidation thesis" for the company. Hill adds that the chance of a Department of Justice challenge to the merger is small in light of the seemingly clear path of the CVS (CVS) - Aetna (AET) merger, but if regulators do seek concessions, he expects the necessary divestitures to be small.
08/23/18
08/23/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ROSENBLATT BOOSTS AMD PRICE TARGET TO STREET HIGH: Rosenblatt analyst Hans Mosesmann raised his price target for AMD (AMD) shares to $30 from $27. Mosesmann's new price target represents the high among Wall Street sell-side analysts. Following the meetings, Mosesmann has renewed conviction in AMD's multi-year double digit growth profile. Further, he's impressed by the analysis investors are doing in the name after years of disregard. AMD is up 4.1% in late morning trading. CANTOR CUTS AETNA TO NEUTRAL: Cantor Fitzgerald analyst Steven Halper downgraded Aetna (AET) to Neutral from Overweight with a price target of $202. The stock now trades at just a 4.6% discount to the implied CVS Health (CVS) acquisition value of about $207 per share, Halper said. He believes the narrowed deal spread reflects an increased likelihood of regulatory approval. Halper cites limited potential upside for his downgrade of Aetna to Neutral. NIELSEN UPGRADED TO NEUTRAL AT GOLDMAN: Goldman Sachs analyst George Tong upgraded Nielsen Holdings (NLSN) to Neutral and raised his price target for the shares to $25 from $20. With activist Elliott Management pushing for a sale and increased deal activity in the Information Services sector, Tong sees increased likelihood of Nielsen being involved in a transaction. His upgrade to Neutral and price target increase come after the analyst incorporated a potential takeover into his model. Nielsen is up 3.3% in late morning trading. IMPERIAL SEES SUBSCRIBER UPSIDE FOR NETFLIX: Imperial Capital analyst David Miller believes Netflix's (NFLX) experiment with ending billing through Apple's (AAPL) app store in 33 countries outside the U.S. likely implies upside to its Q3 international subscriber guidance. The analyst said he has a tough time believing that Netflix would "experiment" with billing infrastructure mid-quarter if it did not believe that its international subscriber levels were trending ahead of guidance. As such, Miller raised his Q3 international subscriber estimate to 4.46M from 4.35M. He kept an Outperform rating on Netflix with a $494 price target. TARGET GETS UPGRADE AND DOWNGRADE: Target (TGT) was upgraded to Outperform from Market Perform at Telsey Advisory, and downgraded to Peer Perform from Outperform at Wolfe Research.
ANTM Anthem
$276.46

0.27 (0.10%)

09/17/18
COWN
09/17/18
INITIATION
Target $318
COWN
Outperform
Anthem initiated with an Outperform at Cowen
Cowen analyst Charles Ryhee initiated Anthem with an Outperform rating citing its unique dominant position in most of its markets because of the Blue Cross/Blue Shield brand. This affords it flexibility to build out its own PBM and pursue a more partnership-based provider strategy, said Ryhee, who has a $318 price target on Anthem shares.
09/10/18
09/10/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ANALYSTS SEE VALUE IN WYNN FOLLOWING PULLBACK: JPMorgan analyst Joseph Greff argued that there is a disconnect between Wynn Resorts' (WYNN) current operating fundamentals and investor sentiment, viewing the recent sector pullback as a buying opportunity. He kept an Overweight rating on Wynn Resorts with a $191 price target. Sharing a similar opinion, Carlo Santarelli at Deutsche Bank said that he would be a buyer of the stock given current valuation and as conditions in Macau remain stable in both the VIP and mass segments. He kept a Buy rating on Wynn Resorts with a $190 price target. AKAMAI UPGRADED TO BUY: DA Davidson analyst Mark Kelleher upgraded Akamai (AKAM) to Buy from Neutral and raised his price target to $93 from $80 after meeting with its management last week to discuss its Q2 results and the company direction going into 2019. The analyst notes that the discussions boosted his confidence in the company's strategic direction as it executes in a transition to a security vendor, saying the company supported by the "enhanced demand" for its security products over the last few quarters. Kelleher further cites the abating headwinds in the company's media segment, which returned to growth after struggling for the past few quarters. CITI DOWNGRADES ANTHEM, UNITEDHEALTH: Citi analyst Ralph Giacobbe downgraded Anthem (ANTM) and UnitedHealth (UNH) to Neutral with unchanged price targets of $290, and $288, respectively. The analyst is taking a more selective view of the managed care sector into year-end and 2019, citing "some reservations" about the commercial risk market. He sees more limited upside to estimates making it difficult to push valuations meaningfully higher "from already-premium levels." SUNTRUST CUTS CONSTELLATION BRANDS TO HOLD: SunTrust analyst William Chappell downgraded Constellation Brands (STZ) to Hold from Buy and lowered his price target to $220 from $260 while also lowering his FY19 EPS view to $9.35 from $9.59 and FY20 to $10.45 from $10.95. The analyst noted that the company's recent $4B investment in Canopy Growth (CGC) may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. Chappell adds that the cannabis business generally has "limited near term catalysts", stating that the stock price may be range bound for an extended time as investors adjust to Constellation Brands' higher leverage ratio. BAIRD DESIGNATES TESLA A FRESH PICK: Baird analyst Ben Kallo designated Tesla (TSLA) as a Fresh Pick as he believes the company's strong fundamentals should drive the shares higher. He said the underlying ramp in Model 3 production will also help push the shares higher ahead of the Q3 deliveries and results. Kallo reiterated his Outperform rating and $411 price target on Tesla shares.
09/10/18
09/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Inogen (INGN) downgraded to Buy from Strong Buy at Needham with analyst Mike Matson citing the potential for slower growth as tougher comps start in the second half of 2018, along with a tighter level of competition from Resmed (RMD) and valuation following the 122% year-to-date run-up in the stock price. 2. UnitedHealth (UNH) and Anthem (ANTM) were downgraded to Neutral from Buy at Citi. 3. Constellation Brands (STZ) downgraded to Hold from Buy at SunTrust with analyst William Chappell saying the company's recent $4B investment in Canopy Growth may "keep a cloud" over the stock for the next few quarters, as there is "little certainty" in the deal's revenue or profit potential. 4. Darden (DRI) downgraded to Neutral from Outperform at Baird with analyst David Tarantino citing its recent strength and recommends a more disciplined approach to buying in the short-term as many restaurant names begin to look extended. 5. Roche (RHHBY) downgraded to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/18
LEER
09/20/18
NO CHANGE
Target $250
LEER
Outperform
Cigna price target raised to $250 from $235 at Leerink
Leerink analyst Ana Gupte raised her price target on Outperform-rated Cigna (CI) to $250 from $235 following meetings with a panel of PBM and Specialty Rx specialists, which increased her bullishness on Cigna and Market Perform-rated Express Scripts (ESRX). In a research note to investors, Gupte says she also came away with raised confidence on the achiveability of the $4B annual drug cost savings from the Express Scripts switch by Anthem (ANTM) to IngenioRx in partnership with CVS (CVS). She adds that smaller independent PBMs still have niche opportunities with smaller regional third-party health plans, noting that Magellan Health (MGLN) is well positioned in this market, though loss of substantial business in Florida Seriously Mentally Ill is a headwind in Rx as well.

TODAY'S FREE FLY STORIES

WVE

Wave Life Sciences

$41.71

0.91 (2.23%)

16:44
01/23/19
01/23
16:44
01/23/19
16:44
Hot Stocks
Breaking Hot Stocks news story on Wave Life Sciences »

Wave Life Sciences down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TST

TheStreet

$2.03

-0.05 (-2.40%)

16:43
01/23/19
01/23
16:43
01/23/19
16:43
Hot Stocks
B. Riley takes 7.3% passive stake in TheStreet »

B. Riley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$35.79

-0.49 (-1.35%)

, EADSY

Airbus

$0.00

(0.00%)

16:40
01/23/19
01/23
16:40
01/23/19
16:40
Hot Stocks
Air Lease announces lease pacts with SAS for Airbus A321-200neo jets »

Air Lease (AL) announced…

AL

Air Lease

$35.79

-0.49 (-1.35%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

BA

Boeing

$358.81

0.9 (0.25%)

16:39
01/23/19
01/23
16:39
01/23/19
16:39
Hot Stocks
Boeing completes first test flight of autonomous passenger air vehicle »

Boeing said it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 28

    May

UVSP

Univest

$22.87

0.18 (0.79%)

16:39
01/23/19
01/23
16:39
01/23/19
16:39
Earnings
Univest reports Q4 EPS 63c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

16:37
01/23/19
01/23
16:37
01/23/19
16:37
General news
API crude inventories for week of January 18 »

API reports that crude…

LOB

Live Oak Bancshares

$15.40

-0.07 (-0.45%)

16:37
01/23/19
01/23
16:37
01/23/19
16:37
Earnings
Live Oak Bancshares reports Q4 EPS 26c, consensus 12c »

Reports Q4 tangible book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

XLNX

Xilinx

$89.55

-0.89 (-0.98%)

16:36
01/23/19
01/23
16:36
01/23/19
16:36
Hot Stocks
Breaking Hot Stocks news story on Xilinx »

Xilinx up 8% to $96.80…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Feb

OHRP

Ohr Pharmaceutical

$0.12

-0.0035 (-2.79%)

16:36
01/23/19
01/23
16:36
01/23/19
16:36
Hot Stocks
Ohr Pharmaceutical announces one-for-twenty reverse stock split »

Ohr Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRMK

Trustmark

$30.50

0.22 (0.73%)

16:36
01/23/19
01/23
16:36
01/23/19
16:36
Earnings
Trustmark reports Q4 EPS 55c, consensus 54c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

CNS

Cohen & Steers

$36.95

0.24 (0.65%)

16:35
01/23/19
01/23
16:35
01/23/19
16:35
Earnings
Cohen & Steers reports Q4 adjusted EPS 56c, consensus 59c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

ADXS

Advaxis

$0.32

-0.0283 (-8.16%)

16:35
01/23/19
01/23
16:35
01/23/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Advaxis 

Advaxis trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVLR

Avalara

$39.72

-0.38 (-0.95%)

16:34
01/23/19
01/23
16:34
01/23/19
16:34
Hot Stocks
Avalara expands into alcoholic beverage compliance through acquisition »

Avalara announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

  • 25

    Feb

  • 03

    Mar

SLM

Sallie Mae

$9.49

0.1 (1.07%)

16:34
01/23/19
01/23
16:34
01/23/19
16:34
Earnings
Sallie Mae sees FY19 EPS $1.22-$1.26, consensus $1.21 »

Sees FY19 private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

BXS

BancorpSouth

$28.54

-0.13 (-0.45%)

16:33
01/23/19
01/23
16:33
01/23/19
16:33
Earnings
BancorpSouth reports Q4 EPS 47c, consensus 55c »

"As we look…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SLM

Sallie Mae

$9.49

0.1 (1.07%)

16:32
01/23/19
01/23
16:32
01/23/19
16:32
Earnings
Sallie Mae reports Q4 adjusted EPS 33c, consensus 27c »

Reports Q4 revenue $383M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

CATY

Cathay General

$37.28

0.12 (0.32%)

16:32
01/23/19
01/23
16:32
01/23/19
16:32
Earnings
Cathay General reports Q4 EPS 80c, consensus 80c »

Return on average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 12

    Mar

CHRA

Charah Solutions

$6.97

0.19 (2.80%)

16:32
01/23/19
01/23
16:32
01/23/19
16:32
Hot Stocks
Charah Solutions names Scott Sewell president, CEO »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHRA

Charah Solutions

$6.97

0.19 (2.80%)

16:31
01/23/19
01/23
16:31
01/23/19
16:31
Hot Stocks
Charah Solutions CEO Charles Price to step down, Scott Sewell to succeed »

Charah Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$132.89

10.55 (8.62%)

, UTX

United Technologies

$117.08

5.85 (5.26%)

16:31
01/23/19
01/23
16:31
01/23/19
16:31
On The Fly
Fly Intel: Wall Street's top stories for Wednesday »

Stocks opened higher…

IBM

IBM

$132.89

10.55 (8.62%)

UTX

United Technologies

$117.08

5.85 (5.26%)

PG

Procter & Gamble

$94.87

4.37 (4.83%)

CMCSA

Comcast

$36.87

1.71 (4.86%)

CMCSK

Comcast

$0.00

(0.00%)

VZ

Verizon

$57.77

0.78 (1.37%)

ORCL

Oracle

$49.25

0.29 (0.59%)

VIPS

Vipshop

$7.08

0.6 (9.26%)

ARAY

Accuray

$4.41

0.44 (11.08%)

WAT

Waters

$229.46

25.94 (12.75%)

TSLA

Tesla

$287.41

-11.39 (-3.81%)

COF

Capital One

$78.19

-5.19 (-6.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 11

    Feb

  • 18

    Feb

  • 25

    Feb

  • 03

    Mar

  • 04

    Mar

BGG

Briggs & Stratton

$13.73

-0.46 (-3.24%)

16:31
01/23/19
01/23
16:31
01/23/19
16:31
Earnings
Briggs & Stratton cuts FY19 EPS view to $1.10-$1.30 from $1.40-$1.60 »

Consensus $1.44. Cuts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

16:30
01/23/19
01/23
16:30
01/23/19
16:30
Options
Preliminary option volume of 17.0M today »

Preliminary option volume…

BGG

Briggs & Stratton

$13.73

-0.46 (-3.24%)

16:29
01/23/19
01/23
16:29
01/23/19
16:29
Earnings
Briggs & Stratton reports Q2 adjusted EPS 20c, consensus 25c »

Reports Q2 revenue $505M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

PTC

PTC

$84.73

-1.14 (-1.33%)

16:29
01/23/19
01/23
16:29
01/23/19
16:29
Hot Stocks
PTC falls over 9% after Q1 earnings and FY19 guidance cut »

Shares of PTC are down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

STL

Sterling Bancorp

$18.29

-0.14 (-0.76%)

16:29
01/23/19
01/23
16:29
01/23/19
16:29
Earnings
Sterling Bancorp reports Q4 EPS 52c, consensus 50c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 11

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.